BEN's AI Play: How Governed Tech is Cracking a High-Stakes Market

WILMINGTON, Del. and MEXICO CITY – June 23, 2026 – In a move that signals a calculated push into one of Latin America's largest healthcare markets, Brand Engagement Network (Nasdaq: BNAI) has advanced its AI-powered medical platform, Skye Salud, to a pivotal Phase 2 clinical evaluation in Mexico. Following a successful specialized trial in rheumatology, the platform is now being stress-tested in the complex, high-volume environment of primary care. This expansion is not merely a technical milestone; it represents a masterclass in strategic market entry, demonstrating how governed, enterprise-grade AI can build a foundation of trust in industries where the stakes are highest.

Developed through a formidable collaboration between BEN, Latin American AI leader Grupo Skye, and the deeply-rooted KNOBLOCH Information Group, Skye Salud is designed to be an evidence-based engine for clinical information. It operates not as a freewheeling generative AI, but as a disciplined tool that grounds its responses in trusted medical literature and clinical guidelines. The initiative's progression underscores a core tenet of building permanent value: navigating turbulent, regulated environments not with speed alone, but with demonstrable strength, transparency, and resilience.

The Architecture of Trust: BEN's 'Engagement Layer' Strategy

At the heart of this initiative is Brand Engagement Network’s distinct philosophy on artificial intelligence. The company focuses on what it calls the “engagement layer of AI,” a crucial stratum where human intent meets complex organizational systems. Powered by its proprietary Engagement Language Model (ELM™), BEN’s technology is engineered for secure, closed-loop environments. This architecture is purpose-built for regulated sectors like healthcare, where accuracy, accountability, and the ability to trace information back to its source are not features, but fundamental requirements.

Unlike consumer-facing AI that often operates with a degree of unpredictability, BEN’s model prioritizes governance. The Skye Salud platform is a direct application of this principle. It provides a conversational interface for physicians while ensuring every piece of information is tethered to vetted medical sources. This creates an auditable trail, mitigating the “black box” problem that makes many professionals wary of AI integration.

"Completion of our Phase 1 rheumatology evaluation represents an important milestone for the Skye Salud initiative," said Tyler Luck, Chief Executive Officer and Co-Founder of BEN. "The Phase 1 evaluation provided valuable insight into platform performance, evidence traceability and response quality across rheumatology use cases. As we enter Phase 2, we are expanding the evaluation into primary care to assess performance across a broader range of clinical questions and use cases."

Luck's emphasis on a methodical, evidence-first approach is telling. "Our focus remains on testing, validation and continuous improvement," he continued. This patient, iterative process is central to BEN's broader strategy. By proving its technology's reliability in a controlled, specialized field first, the company built the credibility needed to tackle the far more diverse challenges of primary care. It’s a playbook for de-risking innovation in fields where failure carries significant human and financial cost.

From Specialist Lab to Primary Care Frontline

The transition from Phase 1 to Phase 2 is a significant leap in complexity and scale. The initial rheumatology trial served as a crucial validation of the platform's core architecture. Under the guidance of Dr. Ruy Carrasco, Chief Medical Information Officer of Skye Salud, this phase confirmed the system's ability to deliver clinically rigorous and traceable responses within a defined specialty.

"The initial pilot within the domain of Rheumatology served as a critical baseline to validate the platform's response architecture, specifically concerning clinical rigor and evidence tractability," noted Dr. Carrasco. Now, the objective is to see how that architecture holds up against the wide-ranging and unpredictable demands of a primary care setting.

This expansion is about more than just adding new medical topics. It involves stress-testing the AI across a “heterogeneous spectrum of clinical presentations,” as Dr. Carrasco describes it. Primary care physicians are generalists who face an enormous breadth of conditions daily. An effective support tool must be able to navigate this diversity without sacrificing the stringent evidence thresholds and source transparency established in Phase 1. The inclusion of Spanish-language clinical content, specifically optimized for Mexico's healthcare environment, is another critical layer of this expansion, ensuring the tool is not just technically sound but also culturally and professionally relevant.

This move directly addresses a critical need. Mexico’s healthcare system, like many in Latin America, grapples with a shortage of doctors and specialists, placing immense pressure on primary care providers. An AI tool that can reliably and quickly surface trusted medical evidence could become an invaluable force multiplier, supporting diagnostic accuracy and improving treatment consistency across a strained system.

A Calculated Play in a Market Ripe for Disruption

BEN and its partners are entering a market that is both promising and paradoxical. Mexico boasts the highest rate of patient AI adoption for health-related purposes in Latin America, with roughly 66% of patients using such tools. The country's digital health market is projected to soar to nearly $10 billion by 2030. Yet, adoption among physicians remains strikingly low, with only around 9% using AI in their practice as of 2024.

This gap represents the core opportunity for Skye Salud. The platform is not another consumer health app; it is a professional-grade tool designed to meet the rigorous standards of clinicians. By focusing on evidence, traceability, and integration into the professional workflow, the initiative aims to bridge the trust deficit that has slowed physician adoption. The strategic partnership with KNOBLOCH Information Group, a trusted name in Mexico's medical community for decades, is instrumental in this effort, providing the market insight and clinical engagement expertise needed to build credibility from the ground up.

The timing also aligns with Mexico's evolving regulatory landscape. While a comprehensive AI-specific law is still in development, the existing health authority, COFEPRIS, provides a pathway for validated Software as a Medical Device (SaMD). BEN's methodical, multi-phase evaluation process is designed to generate precisely the kind of performance and safety data that regulators will demand, positioning Skye Salud for a potential commercial launch built on a foundation of proven efficacy and safety.

The collaboration itself is a model of strategic resilience. It combines BEN’s enterprise-grade AI, Grupo Skye’s regional execution capabilities, and KNOBLOCH’s market access into a single, focused entity. This structure allows the venture to navigate local complexities while leveraging world-class technology. The insights gained from the Phase 2 evaluation will not only guide the platform's future development but will also inform a potential commercialization strategy, with an eye toward expanding this model to other healthcare settings and markets across Latin America.